Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research201 enrolled

Overview

The purpose of this study was to evaluate the safety and intraocular-lowering efficacy of anecortave acetate depot when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

201

Conditions

Open-angle Glaucoma Oular Hypertension

Interventions

Anecortave Acetate Sterile Suspension, 30 mg/mLDRUG

Single administration by anterior juxtascleral depot

Anecortave Acetate Sterile Suspension, 60 mg/mLDRUG

Single administration by anterior juxtascleral depot

Anecortave Acetate Sterile Suspension, 75 mg/mLDRUG

Single administration by anterior juxtascleral depot

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients 18 years of age or older with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation) or ocular hypertension. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patients with any form of glaucoma other than open-angle. * Other protocol-defined exclusion criteria may apply.

Locations (1)

Charleston

Charleston, South Carolina, United States

Outcomes

Primary Outcomes

Mean Intraocular Pressure at 8 am

Time frame: Up to 6 months

Secondary Outcomes

Percent of Patients Who Remained Rescue Medication-Free at Month 3 (8 am)

Time frame: Month 3, 8 am

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.